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Determination of the hepatitis C virus (HCV) genotype for infected patients increasingly has become
accepted as the standard of care. Genotype assignment helps in assessing disease prognosis and assists in
establishing the appropriate duration of treatment. The great genetic diversity of HCV, with 11 major
genotypes and >70 subtypes, contributes to the technical difficulty of genotype testing. While the “gold
standard” for testing is nucleic acid sequencing, a variety of hybridization assays, including the line probe
assay, have been developed to provide more rapid and accessible forms of testing. The aim of this study was
to determine whether denaturing high-performance liquid chromatography (dHPLC) could be used as a
clinical method for distinguishing HCV genotypes 1, 2, 3, and 4. A portion of the 5 untranslated region of the
HCV genome was amplified by heminested multiplex reverse transcription PCR. The two amplicons then were
analyzed by dHPLC analysis and compared to the genotypes determined by sequence analysis. After 115
specimens were analyzed as standards, 200 masked specimens (specimens whose identity was not known before
testing) were analyzed to determine the concordance of the assay. The assay had a concordance of 96% at the
genotype level and a concordance of 87% at the subtype level. However, the dHPLC method was not as accurate
as other reported methods of HCV genotyping. This is the first time that HCV genotyping has been performed
by dHPLC.
Hepatitis C virus (HCV) is a single-stranded RNA virus of
the family Flaviviridae that causes both acute and chronic hep-
atitis. Approximately 85% of acute cases progress to chronic
infection. Patients with chronic infection are at substantial risk
for the development of cirrhosis and eventually hepatocellular
carcinoma. The Centers for Disease Control and Prevention
estimates that in the United States alone, approximately 3.8
million people are chronically infected. Chronic HCV infec-
tion is the most common disease leading to liver transplant in
the United States. HCV has a positive-sense genome of ap-
proximately 9.4 kb and which encodes a polyprotein of 300
amino acids (15, 20). Like the genomes of other single-
stranded RNA viruses, the HCV genome is vulnerable to high
rates of mutational change.
Eleven genotypes have been identified for HCV, with ap-
proximately 70 subtypes, based upon the sequence variability
identified within its 5 untranslated region (UTR) (11). The
most common subtypes of HCV seen within the continental
United States are 1a, 1b, 2a, 2b, and 3a. There does appear to
be a correlation between the type of HCV and the efficacy of
treatment with pegylated alpha interferon and ribavarin (16,
23). HCV genotypes 2 and 3 are more sensitive to treatment,
making HCV genotyping important (1, 5, 8).
Denaturing high-performance liquid chromatography
(dHPLC) is a method of separating nucleic acids based upon
their sequence composition. It is primarily a tool to identify
mutations or polymorphisms based upon separation of het-
eroduplexes from homoduplexes under partially denaturing
conditions (21). For example, a common application is
screening for heterozygosity in organisms that have pairs of
chromosomes (6, 14, 17, 22). However, it is more difficult to
identify or genotype microorganisms involved in infectious
disease. The unpaired genome of microorganisms requires
an exogenous template to form heteroduplexes. Exogenous
templates have been used to discriminate between different
bacterial species (7) and to genotype a meningococcus out-
break (19).
HCV genotyping usually is performed by a line probe assay
or direct sequencing (3, 4, 12, 15). Additional methods include
a microarray assay (24), modifying the HCV Amplicor monitor
test for genotyping (13), heteroduplex analysis (20), and probe
melting curve analysis (2, 18). Here we describe a novel assay
that uses a heminested multiplex reverse transcription (RT)-
PCR to distinguish HCV genotypes 1, 2, 3, and 4 by dHPLC
analysis without heteroduplex formation.
MATERIALS AND METHODS
Human plasma samples. The samples used in this study were submitted to
ARUP Laboratories for HCV genotyping. Serum or EDTA-treated plasma was
centrifuged, separated from cells, frozen at 20°C within 2 h of collection, and
then shipped to ARUP Laboratories. A total of 315 samples were obtained, and
any identifying material was removed according to Health Insurance Portability
and Accountability Act regulations. Of those samples, 115 were used to deter-
mine parameters for genotyping masked samples (samples whose identity was
not known before testing). The remaining 200 samples were masked so that the
concordance of the assay could be determined.
HCV genotyping by PCR and sequencing. HCV sequencing was performed at
the Sequencing Laboratory at ARUP Laboratories by standard methods. HCV
RNA was extracted by using an Amplicor HCV preparation kit, version 2.0
(Roche, Indianapolis, Ind.), and a 245-bp region of the 5 UTR was amplified by
using an Amplicor HCV amplification kit, version 2.0 (Roche). The amplified
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nucleic acid was sequenced bidirectionally by using dye terminator chemistry
with an ABI Prism 377 DNA sequencer (Applied Biosystems, Foster City, Calif.).
Genotyping results were based on a comparison with a database derived from
GenBank sequences, published information, and in-house sequencing (11).
RNA extraction. HCV RNA was extracted from plasma samples by using a
QIAamp viral RNA extraction kit (Qiagen, Valencia, Calif.) according to the
manufacturer’s instructions. In brief, virions were lysed, and the RNA genomes
were captured in the spin columns provided. The HCV RNA was washed and
then eluted by incubation of the spin columns for 1 min in 60 l of sterile
molecular-grade water followed by 1 min of centrifugation at 6,000 g and room
temperature. The HCV RNA was collected in a clean 1.5-ml Eppendorf tube and
stored at 20°C until used.
Heminested multiplex RT-PCR. The extracted HCV RNA was amplified by a
heminested multiplex RT-PCR approach with a Qiagen OneStep RT-PCR kit. A
heminested approach was implemented because it was simple, and the use of two
amplicons with different melting characteristics made it possible to differentiate
genotypes that were not resolvable with either amplicon alone. The sequence of
forward primer HCV5UTR01F was 5-GTGAGTACACCGGAAT-3, the se-
quence of reverse primer HCV5UTR02R was 5-ATCCAAGAAAGGACCC-3,
and the sequence of reverse primer KY78 (10) was 5-CTCGCAAGCACCCT
ATCAGGCAGT-3 (Fig. 1). The heminested RT-PCR leads to both 45- and
153-bp amplicons. Reaction mixtures contained Qiagen OneStep RT-PCR
buffer, 2 mM GeneAmp deoxynucleoside triphosphate blend (0.4 mM dATP,
dCTP, and dGTP and 0.8 mM dUTP) (Applied Biosystems), 3.0 mM MgCl2, 1
M HCV5UTR01F, 1 M HCV5UTR02R, 0.25 M KY78, 0.01 U of uracil
DNA glycosylase (Roche)/l, 0.3 U of RNase inhibitor (Roche)/l, Qiagen
OneStep RT-PCR enzyme mix, 2 l of extracted HCV RNA, and molecular-
grade water to 25 l. Thermal cycling was performed with a 96-well GeneAmp
PCR system 9700 (Applied Biosystems) as follows: an initial 50°C hold for 10
min; a 60°C hold for 30 min; a 95°C hold for 15 min; 40 cycles of 95°C for 30 s,
54°C for 30 s, and 72°C for 1 min; and a 72°C hold for 10 min.
dHPLC. dHPLC was performed by using a WAVE system (Transgenomic,
Omaha, Nebr.) equipped with a DNASep high-throughput cartridge, an L-761
online degasser, a D-7000 interface module, an L-7100 pump, an L-7250 au-
tosampler, a PCR7250 Peltier cooling rack, a WAVE accelerator, an L-7300
column oven, and an L-7400 UV detector. All buffers were supplied by Trans-
genomic. Ten microliters of RT-PCR amplicon was loaded without treatment
into the cartridge by an autosampler. The amplicon was eluted from the column
with a linear acetonitrile gradient in 0.1 mM triethylammonium acetate buffer
(TEAA; pH 7) (Transgenomic) at a constant flow rate of 0.9 ml/min. The
acetonitrile gradient was formed by mixing 0.1 mM TEAA and 0.1 mM TEAA
containing 25% (vol/vol) acetonitrile. The 45-bp amplicon was eluted from the
column with a gradient of 7.5 to 10% (vol/vol) acetonitrile. The 153-bp amplicon
was eluted from the column with a gradient of 11.5 to 13.75% (vol/vol) aceto-
nitrile. Acetonitrile gradients lasted for 4.5 min at a flow rate of 0.9 ml/min. The
column then was cleaned with 75% (vol/vol) acetonitrile for 0.5 min with the
WAVE accelerator and equilibrated with loading conditions for 0.9 min before
the next sample was loaded. Carryover contamination did not appear to be a
problem with this cleaning procedure. The temperature of the oven was fixed at
55°C for analysis of the 45-bp amplicon and at 63.4°C for analysis of the 153-bp
amplicon. These temperatures were determined by a combination of evaluation
with melting simulation software (Wavemaker 4.1) and empirical experiments.
Elution of the amplicon was detected by measuring the absorbance at 260 nm.
HPLC System Manager software regulated every parameter of the WAVE sys-
tem during analysis and stored the data.
One specimen each of genotypes 1a, 1b, 2a, 2b, 3a, and 4 was included in every
separate dHPLC run of masked samples to control for between-experiment
variations. If the retention time of the standards was not within 0.15 min of the
expected value, the results were not used for genotyping. In addition, these
standards were used routinely to check for carryover contamination by examining
the traces to determine whether any of the previously injected standard could be
seen in the following trace.
Data analysis of masked samples. The majority of samples were tested only
once. However, if a genotype was ambiguous, then the sample was retested. If a
sample had characteristics that did not fit the parameters for defining the HCV
genotypes described in Table 1, it was deemed to be ambiguous. If the repeat
data still were difficult to interpret, the assigned genotype was based upon the
repeat run. The second run was used as the basis for the genotype assignment
because it produced better-quality data.
RESULTS
Genotyping of HCV standards by dHPLC. The RT-PCR
approach used in this study resulted in two products being
amplified from a single reaction. These two products, 45- and
153-bp amplicons, could be visualized by dHPLC under non-
denaturing conditions at 50°C (Fig. 2). However, because the
optimal elution characteristics for the amplicons were so dif-
ferent, the data for the two amplicons were acquired separately
with different temperatures and different acetonitrile gradi-
ents.
The 115 specimens used as standards were assigned a geno-
type based on sequence analysis. There were 30 type 1a, 21
type 1b, 12 type 2a, 18 type 2b, 22 type 3a, and 12 type 4 HCV
specimens. Genotyping appeared possible when both the re-
tention time and the shape of the dHPLC trace were consid-
ered.
153-bp amplicon standards. No data were obtained for 3 of
115 specimens because the specimens had a relatively low
HCV RNA template concentration (3.9 log IU/ml). Mean
retention times and standard deviations for the genotypes were
FIG. 1. Locations and sequences of primers used in the HCV heminested multiplex RT-PCR. (A) Sequence of HCV 5 UTR (9) around
amplicons of interest, showing the positions of primers HCV5UTR01F, HCV5UTR02R, and KY78. The primer locations are outlined in the boxes,
and the numbers above the sequences are nucleotide positions with respect to the starting nucleotide of the translated region.
TABLE 1. Parameters used to genotype unknown HCV specimensa
Retention time (min) for the following
amplicon: Genotype







a Parameters are described for each amplicon separately but must both be
present in the same sample for the sample to be allocated into a specific geno-
type.
b The trace usually has a high absorbance and a shoulder.
c The trace sometimes has a sharp spike associated with the trailing edge of the
peak.
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as follows: 1a, 4.75  0.23 min; 1b, 5.20  0.22 min; 2a, 4.48 
0.17 min; 2b, 3.25  0.17 min; 3a, 4.21  0.24 min; and 4, 4.99
 0.27 min. The standard deviations of the retention times
were 0.3 min and appeared to correlate with sequence vari-
ations seen among specimens of the same genotype. Based on
the retention time results, the 153-bp amplicon could be used
to discriminate type 2b from types 1a, 1b, 2a, 3a, and 4. Types
1a, 1b, 2a, 3a, and 4 could not be completely discriminated by
retention time alone.
The dHPLC traces often had more than one peak (Fig. 3A).
The last peak was used to determine the retention time. The
traces usually had broad peaks due to partial denaturation and
melting of the amplicon at the temperature chosen for analysis.
At nondenaturing temperatures or more denaturing tempera-
tures, the amplicons appeared as single well-defined peaks but
were not adequate for genotyping because of a loss of resolu-
tion between different HCV types.
The shape of the dHPLC traces was used to aid in discrim-
ination of the genotypes. For example, some specimens of type
2a had a sharp spike at the trailing edge of the peak, compared
to other genotypes, which all had round broad peaks (Fig. 3A).
This sharp spike was not observed in the other genotypes
tested. In addition, specimens of type 2b usually had a much
higher absorbance and a shorter retention time than all of the
other genotypes. Type 3a specimens were generally the next
genotype to elute. However, some type 3a and 1a specimens
had overlapping retention times and therefore were not dis-
tinguishable by the shape of the dHPLC trace. Furthermore,























FIG. 2. dHPLC trace of HCV heminested multiplex RT-PCR
products under nondenaturing conditions at 50°C. The HCV specimen
was type 1b. The elution of nucleic acid is based upon size in this
analysis, so the first peak, at 2.9 min, is the 45-bp amplicon, and the
peak at 9.3 min is the 153-bp amplicon.
FIG. 3. Representative dHPLC traces for each genotype and a no-template control. (A) Analysis of the 153-bp amplicon carried out at 63.4°C
with a 11.5 to 13.75% (vol/vol) acetonitrile gradient. (B) Analysis of the 45-bp amplicon carried out at 55°C with a 7.5 to 10%(vol/vol) acetonitrile
gradient.
160 LIEW ET AL. J. CLIN. MICROBIOL.
some type 1a, 1b, and 4 specimens were difficult to discriminate
with the 153-bp amplicon. Usually, the retention times of the
type 1b and 4 specimens were shorter than those of the type 1a
specimens (Fig. 3A).
45-bp amplicon standards. No data were obtained for 3 of
115 specimens tested. As for the 153-bp amplicon, this result
was due to a relatively low HCV RNA template concentration
(3.9 log IU/ml). Mean retention times and standard devia-
tions for the genotypes were as follows: 1a, 5.35 0.11 min; 1b,
5.36  0.15 min; 2a, 4.85  0.11 min; 2b, 4.58  0.14 min; 3a,
5.7  0.05 min; and 4, 5.62  0.11 min. The retention times
measured for this amplicon, in comparison to those obtained
for the 153-bp amplicon, had smaller standard deviations. This
finding correlates with the smaller size of the amplicon and less
sequence variation found within a genotype. From the reten-
tion times, types 2a and 2b could not be distinguished from
each other but could be distinguished from types 1a, 1b, 3a,
and 4. Type 3a could be distinguished from types 1a and 1b but
not from type 4. In contrast to the results obtained with the
153-bp amplicon, types 1a and 1b were indistinguishable.
The shapes of the traces obtained with the 45-bp amplicon
were more uniform among all of the genotypes and were not as
informative as the shapes obtained with the 153-bp amplicon
(Fig. 3B). More information was obtained from the actual
retention times. Even though the retention times for types 1a
and 1b were indistinguishable, it was possible to distinguish
these types from type 3a. However, types 3a and 4 were not
distinguishable with the 45-bp amplicon.
Combined results for genotyping. Each of the amplicons by
itself could discriminate some of the HCV types, but combin-
ing the results improved the discrimination considerably (Fig.
4). Type 2a and 2b specimens were well discriminated from the
other HCV types, except for one type 2a specimen that was
very close to a type 1a specimen. Type 3a specimens were
relatively well clustered away from the other HCV types, apart
from a few specimens that overlapped with some type 4 spec-
imens. Type 4 specimens were not easy to identify, with some
being very close to types 1a and 1b. Type 1a and 1b specimens
clustered together as a large group, with significant overlap.
In order to standardize the assignment of HCV genotypes,
the following method was used (Table 1). To make a genotype
designation, parameters from both amplicons were used. First,
the unknown traces were compared to the standards used in
the same experimental run, to examine them for overlap and
shape. If a genotype could not be assigned from trace compar-
isons, then the retention time cutoffs were used to assign a
genotype.
Masked specimens. Out of the 200 masked specimens, 3
could not be genotyped because of a low HCV load. For
specimens that were amplified successfully, the results for 190
of 197 specimens (96%) were concordant with the sequence
analysis at the major genotype level. Seventeen percent (34 of
200) of specimens had to be retested. For about half of these
(15 of 34), the first and second runs did not agree, and the
second run was used. The remaining specimens were con-
firmed by the subsequent run. The discrepant results are de-
scribed in Table 2.
The sources of error fell into two categories. Some speci-
mens were difficult to assign, and although they were correctly
identified on the first run, they were misidentified on the sec-
ond run (specimens 1 and 2). However, one specimen that
appeared to be unambiguous was misidentified and was not
retested (specimen 3). The second category of error resulted
from unexpected sequence variants not observed in the train-
ing set (specimens 4 to 7).
At the subtype level, the number of specimens for which
results were concordant dropped to 171 of 197 (87%). The
majority of errors were made between types 1a and 1b. One
type 2a specimen was incorrectly identified by dHPLC as type
2b. Analysis of the sequence data for this specimen identified
FIG. 4. dHPLC retention times for the 153- and 45-bp amplicons of the 5 UTR of HCV. The data are from the specimens used as stan-
dards.
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a single base change (C117T) in the 153-bp amplicon. This was
another sequence variant not identified in the population of
standards used.
DISCUSSION
One advantage of HCV genotyping by dHPLC is that no
external probes or dyes are required. The method is simple,
does not require heteroduplex formation, and is partially au-
tomated, reducing hands-on time and cost. However, several
disadvantages and limitations were found in this study. Every
dHPLC run must include a sample of each genotype as a
reference. There is a contamination risk because tubes must be
opened in order to inject the amplicon into the dHPLC car-
tridge. Perhaps most importantly, the current protocol is only
96% specific at the major genotype level and 87% specific at
the subtype level. Consistent with what another group of in-
vestigators found when comparing the line probe assay to se-
quencing (3), types 1a and 1b are difficult to distinguish. It is
also difficult to distinguish correctly types 1 and 3 from type 4.
This study also did not include any examples of type 5 or 6, so
it is unknown whether these particular genotypes could be
distinguished from the other genotypes. In addition, as in other
assays that are not based on sequencing, polymorphisms or
mutations that have not been observed previously may contrib-
ute to incorrect genotype assignment.
The dHPLC method reported here is not as specific as other
techniques for HCV genotyping. Zhao et al. (24) reported a
93.3% concordance rate at the subtype level when comparing
microarray genotyping with sequencing of the 5 UTR for a
population of 60 samples of types 1b, 2a, 2b, 3a, and 3b.
Schro¨ter et al. (18) reported a 100% concordance rate when
amplifying the 5 UTR and genotyping with three pairs of
hybridization probes by using the LightCycler compared to
sequencing of the 5 UTR for a population of 190 samples of
types 1, 2, 3, and 4. Bullock et al. (2) reported that 110 of 111
samples (99%) were concordant at the genotype level for types
1, 2, 3, and 4 and that 108 of 110 samples (98%) were concor-
dant at the subtype level. Their study compared a LightCycler
assay amplifying the 5 UTR with a single set of fluorescence
energy transfer probes in the line probe assay. The lowest viral
titer that could be successfully genotyped in this study was
approximately 4 log IU/ml. This titer is comparable to that in
other assays because one study reported detection to 3 log
IU/ml (18) and another study reported detection to 4 log IU/ml
with their assay and the line probe assay (2).
Despite its current limitations, HCV genotyping by dHPLC
is a good screening tool at the major genotype level. For
example, types 2 and 3 can be distinguished from type 1 with a
false-positive rate of 2.5% and a false-negative rate of 1%.
Furthermore, the current assay could be improved by including
other regions of the HCV genome that discriminate genotypes
and subtypes better. Ideally, the assay would be refined to a
single amplicon that would require analysis at a single temper-
ature. These parameters present a challenge for all HCV geno-
typing assays, as the HCV genome is so variable.
The results reported in this study provide a novel approach
to the genotyping of HCV and potentially other viruses with
single-stranded genomes. As a screening tool, dHPLC can be
used to determine the major genotype but not the viral sub-
type. This approach does not require external heteroduplex
formation, reducing the chance of contamination and elimi-
nating the effort of mixing genotypes either before or after
amplification. However, compared to other reported methods
of HCV genotyping, the dHPLC method reported here is not
as specific. dHPLC genotyping without heteroduplex forma-
tion is most applicable to infectious agents that do not have
much genetic variation.
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